A previous study found that MCT2 expression was reduced in several neurological diseases (Bosshart et al. 2020; Felmlee et al. 2020); however, it remains unclear whether MCT2 activation can prevent or treat stroke. Here, SLC16A7 is linked to nervous system disorder.